The National Comprehensive Cancer Network (NCCN) has released international recommendations and guidelines for diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and studies are being conducted worldwide.
Should your doctor notice signs of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) from breast imaging such as fluid, lymph node swelling, or a mass, the guidelines recommend for a fluid aspiration of at least 50ml using a needle. The fluid is then to be sent for testing that should include CD30 immune staining, cytology, and flow cytometry.
According to the American Society of Plastic Surgeons (ASPS), "CD30 is a substance that indicates the presence of this kind of cancer. Immune staining is a way of checking for CD30. CD30 testing provides information critical for pathologists. Doctors should try to confirm a diagnosis before surgery." Knowing your results ahead of surgery is advantageous in the treatment of BIA-ALCL.
Remember that BIA-ALCL and breast implants are all relatively new territory for medical professionals and it may take years to come to uncovering all the questions we have as patients. if you cannot find all the answers you are looking for from your medical professional, be diligent and ask another medical professional.
All posts are intended strictly for educational purposes. It is not intended to make any representations or warranties about the outcome of any procedure. It is not a substitute for a thorough in-person consultation with a medical professional. If you have questions about your personal medical situation, please call your healthcare provider.
Commentaires